---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-076066"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:19:50.924181+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q2 net loss $6.4M; requests FDA Type A meeting for CRL on OLC

## Summary
- Net loss of $6.4M vs net income of $3.0M in Q2 2024; R&D expenses down to $1.8M.
- Cash and equivalents $22.3M as of June 30, 2025; runway expected into H2 2026.
- Type A meeting requested with FDA to resolve CRL for oxylanthanum carbonate (OLC).
- Pivotal OLC data published in CJASN: >90% patients achieved phosphate control with low pill burden.

## SEC filing metadata
- accession: 0001213900-25-076066
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/0001213900-25-076066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/ea0253163-8k_unicy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-076066
- JSON: https://secwatch.observer/filing/0001213900-25-076066.json
- Plain text: https://secwatch.observer/filing/0001213900-25-076066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.